| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Wendy Lim | |
| P2860 | cites work | Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. | Q46008611 |
| Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis | Q47351547 | ||
| Elevated partial antiphospholipid score is a strong risk factor for thrombosis in patients with systemic lupus erythematosus: a validation study. | Q50737245 | ||
| Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. | Q53190445 | ||
| Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS) | Q57624052 | ||
| Antiphosphatidylserine/prothrombin antibodies in primary antiphospholipid syndrome | Q61649492 | ||
| Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 | ||
| The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients | Q79765195 | ||
| Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity | Q80213989 | ||
| A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis | Q81831105 | ||
| Antibody profiles for the diagnosis of antiphospholipid syndrome | Q81873167 | ||
| Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies | Q83389363 | ||
| Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders | Q84227527 | ||
| Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events | Q85002100 | ||
| Is there an association between complement activation and antiphospholipid antibody-related thrombosis? | Q85025574 | ||
| Assessing bleeding risk in patients taking anticoagulants | Q24619070 | ||
| Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis | Q26771581 | ||
| The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis | Q26995669 | ||
| A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) | Q28174751 | ||
| A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome | Q28193536 | ||
| Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals | Q28210153 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients | Q33377847 | ||
| 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends | Q34400373 | ||
| Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature | Q34977289 | ||
| The epidemiology of venous thromboembolism. | Q35157791 | ||
| A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies | Q37020336 | ||
| A randomized trial of rosuvastatin in the prevention of venous thromboembolism | Q37262627 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review | Q38113968 | ||
| Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism? | Q38169701 | ||
| Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review | Q38232261 | ||
| Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. | Q38280730 | ||
| Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials | Q38584212 | ||
| Emerging Therapies in Antiphospholipid Syndrome | Q38782057 | ||
| Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force | Q38804286 | ||
| APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking | Q39612633 | ||
| Clinical course of high-risk patients diagnosed with antiphospholipid syndrome | Q39934417 | ||
| beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the honolulu heart program | Q40693493 | ||
| Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature | Q41542983 | ||
| Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. | Q41595596 | ||
| Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. | Q41939439 | ||
| Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. | Q43626449 | ||
| Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: a nationwide cohort study | Q43846279 | ||
| Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients | Q43901099 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| GAPSS: the Global Anti-Phospholipid Syndrome Score | Q44993606 | ||
| Risk factors for arterial thrombosis in antiphospholipid syndrome. | Q45084769 | ||
| P433 | issue | 1 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 707-713 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Hematology / the Education Program of the American Society of Hematology | Q26842068 |
| P1476 | title | Prevention of thrombosis in antiphospholipid syndrome | |
| P478 | volume | 2016 |
Search more.